We’re another step closer to bringing innovative new options to people living with treatment-resistant depression. Read about new Phase 2a results from atai Life Sciences & BeckleyPsytech: ir.atai.com/news-release...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression | Atai...
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningfu...
ir.atai.com
September 23, 2025 at 1:39 PM
We’re another step closer to bringing innovative new options to people living with treatment-resistant depression. Read about new Phase 2a results from atai Life Sciences & BeckleyPsytech: ir.atai.com/news-release...
#depression #mentalhealth #drugdevelopment #antidepressant #MajorDepressiveDisorder #MDD #BeckleyPsytech #psychedelics #licensedmedicines #ELE101 #clinicaltrial #Phase2astudy #IVformulation #psilocinbenzoate #MDDpatients #MADRSscores #rapidactingMDDtreatment
pharmatimes.com/news/beckley...
pharmatimes.com/news/beckley...
Beckley Psytech announces positive results for ELE-101 in depression trial - PharmaTimes
Phase 2a study shows promising antidepressant effects
pharmatimes.com
December 17, 2024 at 12:55 PM
UK #psychedelicmedicines developer #BeckleyPsytech is preparing to take its psychedelic medicine for severe #depression into a pivotal trials programme on the back of a positive phase 2b readout.
Beckley psychedelic hits the target, unlocking atai merger
The proposed merger between Beckley Psytech and atai is unlocked as a psychedelic for depression hits all its endpoints in a phase 2b trial.
buff.ly
July 1, 2025 at 4:01 PM
UK #psychedelicmedicines developer #BeckleyPsytech is preparing to take its psychedelic medicine for severe #depression into a pivotal trials programme on the back of a positive phase 2b readout.